Aktis Oncology, Inc. (AKTS) financial statements and ratios from SEC XBRL: revenue $1.49M (latest fiscal year), net margin -2957.6%, revenue growth 111.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.49M |
| Net Margin | -2957.6% |
| Revenue Growth (YoY) | 111.4% |
| EPS Growth (YoY) | -98.0% |
| FCF Growth (YoY) | 29.3% |
| Price / Book | 2.97 |
| Price / Sales | 148.95 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.6 |
AKTS overview · AKTS earnings · AKTS KPIs · AKTS documents · AKTS ownership · AKTS peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.